Vor Biopharma raises $75M via private placement with TCGX for telitacicept development

Vor Biopharma Inc.

Gross proceeds of $75M from sale of 5.34M shares at $14.05/share to TCGX affiliates.
Closing expected March 30, 2026; no placement agent used.
Proceeds to advance Phase 3 trials for myasthenia gravis and primary Sjögren's disease.
TCGX managing partner expresses confidence in telitacicept's differentiated profile.
Registration rights agreement to file resale registration statement within 30 days.

item 1.01 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Vor Biopharma Inc. issued 5,338,078 shares of common stock to TCGX for $14.05 per share.

Security: common stock
Shares: 5,338,078 shares
Purchaser: TCGX
Consideration: $14.05 per share

Exact text from the filing

entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at a price of $14.05 per share in a private placement.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vor Biopharma Inc. entered into Securities Purchase Agreement with entities affiliated with TCGX valued at approximately $75.0 million (effective 2026-03-26).

Action: entry
Agreement: equity purchase
Counterparty: entities affiliated with TCGX
Value: approximately $75.0 million
Effective: 2026-03-26

Exact text from the filing

On March 26, 2026, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with TCGX (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 5,338,078 shares (the “Shares”) of the Company’s common stock, at a price per Share of $14.05, for gross proceeds of approximately $75.0 million (the “Private Placement”).

View on SEC.gov

43 equity issuances filed in the last 30 days. Browse all equity issuances →

Vor Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-127609

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.